CFM
AMLX icon

Catalyst Funds Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Catalyst Funds Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,905
Closed -$52.8K – 444
2025
Q1 		$52.8K Buy
+14,905
New +$53K 0.01% 412
2024
Q4 		– Sell
-7,500
Closed -$24.3K – 350
2024
Q3 		$24.3K Hold
7,500
– – 0.01% 1037
2024
Q2 		$14.3K Buy
+7,500
New +$14.5K ﹤0.01% 801

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Catalyst Funds Management's AMLX Position: Q2 2025 in Review

Catalyst Funds Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 14,905 shares — an estimated $52.8K sold.

Catalyst Funds Management first reported a position in AMLX in Q2 2024 and held it in 3 quarters. The position peaked at $52.8K in Q1 2025. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Catalyst Funds Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 14,905 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $52.8K.
  • Catalyst Funds Management first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Amylyx Pharmaceuticals position peaked at $52.8K in Q1 2025.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Catalyst Funds Management's 13F filing for Q2 2025, filed 12 Aug 2025.